Alterity Therapeutics Limited

0.6297-0.0095-1.49%Vol 105.97K1Y Perf -53.34%
Jun 24th, 2022 15:44 DELAYED
BID0.6100 ASK0.6298
Open0.6392 Previous Close0.6392
Pre-Market- After-Market0.64
 - -  0.01 1.64%
Target Price
4.00 
Analyst Rating
Strong Buy 1.00
Potential %
535.22 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     68.61
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     55.33
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.29 
Earnings Rating
Market Cap25.26M 
Earnings Date
2nd Oct 2020
Alpha-0.01 Standard Deviation0.21
Beta1.33 

Today's Price Range

0.59790.6392

52W Range

0.58012.75

5 Year PE Ratio Range

-2.70-1.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
4.95%
1 Month
-3.42%
3 Months
-18.06%
6 Months
-23.21%
1 Year
-53.34%
3 Years
-50.80%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ATHE0.6297-0.0095-1.49
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
11.50
11.90
0.00
0.00
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
284.18K
282.81K
-7 591.60
-
RevenueValueIndustryS&P 500US Markets
-3 626.00
0.00
-17.72
-13.83
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume105.97K
Shares Outstanding40.11K
Shares Float40.11M
Trades Count228
Dollar Volume65.05K
Avg. Volume72.56K
Avg. Weekly Volume74.83K
Avg. Monthly Volume58.47K
Avg. Quarterly Volume84.39K

Alterity Therapeutics Limited (NASDAQ: ATHE) stock closed at 0.6297 per share at the end of the most recent trading day (a -1.49% change compared to the prior day closing price) with a volume of 105.97K shares and market capitalization of 25.26M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Alterity Therapeutics Limited CEO is Geoffrey Paul Kempler.

The one-year performance of Alterity Therapeutics Limited stock is -53.34%, while year-to-date (YTD) performance is -12.54%. ATHE stock has a five-year performance of %. Its 52-week range is between 0.5801 and 2.75, which gives ATHE stock a 52-week price range ratio of 2.29%

Alterity Therapeutics Limited currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 0.83, a price-to-sale (PS) ratio of -6 637.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.38%, a ROC of -35.28% and a ROE of -35.32%. The company’s profit margin is -%, its EBITDA margin is 282 808.00%, and its revenue ttm is $-3 626.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Alterity Therapeutics Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Alterity Therapeutics Limited’s next earnings report date is -.

The consensus rating of Wall Street analysts for Alterity Therapeutics Limited is Strong Buy (1), with a target price of $4, which is +535.22% compared to the current price. The earnings rating for Alterity Therapeutics Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alterity Therapeutics Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alterity Therapeutics Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 28.65, ATR14 : 0.07, CCI20 : -100.11, Chaikin Money Flow : -0.26, MACD : -0.02, Money Flow Index : 75.20, ROC : -10.68, RSI : 43.18, STOCH (14,3) : 16.55, STOCH RSI : 0.83, UO : 29.29, Williams %R : -83.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alterity Therapeutics Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Alterity Therapeutics Limited

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).

CEO: Geoffrey Paul Kempler

Telephone: +61 393494906

Address: 460 Bourke Street, Melbourne 3000, VIC, AU

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

74%26%

Bearish Bullish

69%31%

News

Stocktwits